News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(USGovernment-News.Com, June 28, 2013 ) New York, NY – The attorneys working with ClassAction.org are currently investigating potential lawsuits on behalf of Byetta users who were diagnosed with pancreatic cancer. It has been alleged that the drug, used to lower blood sugar levels in patients with Type 2 diabetes, can increase a patient’s risk of developing pancreatic cancer. If you or a loved one has used Byetta and has been diagnosed with pancreatic cancer, you may be able to take legal action against the makers of the drug to recover financial compensation for medical bills and other losses. Free online consultations are now being offered at ClassAction.org, a website dedicated to keeping patients informed about product alerts, recalls and emerging litigation. Please visit http://www.classaction.org/byetta.html and fill out the form on the right for more information.
A number of lawsuits have been filed on behalf of Byetta users alleging that Amylin Pharmaceuticals and Eli Lilly and Co. knew that Byetta can cause life-threatening pancreatic cancer and failed to adequately warn both patients and doctors about this risk. According to one lawsuit, the makers of Byetta did not even mention “pancreatic cancer” on the drug’s product insert. It has also been alleged that doctors were not warned or advised to institute monitoring procedures to indicate initial signs of changes within the pancreas. Even if the manufacturers had provided adequate warnings, the benefits of Byetta do not outweigh its risks, especially with the availability of other diabetes drugs, the suits allege.
In March 2013, the FDA announced that it would be “evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis. . .and pre-cancerous cell changes” in Type 2 diabetes patients treated with drugs in the incretin mimetic class, which includes both Byetta and Januvia. The agency has not reached any new conclusions about the safety risks with these drugs, but issued the communication to inform the public and medical community that they would “obtain and evaluate this new information.” If you or a loved one has been diagnosed with pancreatic cancer after using Byetta, you may have legal recourse to collect financial compensation for your losses. For more information, please visit ClassAction.org.
About Class Action.org
Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit http://www.classaction.org today for a no cost, no obligation case evaluation and information about your consumer rights.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
